Linked Life Data

10234572

Source:http://linkedlifedata.com/resource/pubmed/id/10234572

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1999-7-6
pubmed:abstractText
Osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) is a soluble member of the tumor necrosis factor receptor family of proteins and plays an important role in the negative regulation of osteoclastic bone resorption. Whether OPG/OCIF circulates in human blood and how its level changes under pathological conditions is not known. To address these issues, a panel of monoclonal antibodies was generated against recombinant OPG/OCIF and screened for reactivity with solid-phase monomeric and homodimeric forms of the recombinant protein. Antibodies that showed high affinity for both forms of OPG/OCIF and those that selectively recognized the homodimer were identified, enabling development of two types of sensitive enzyme-linked immunosorbent assay (ELISA): one that detects both forms of OPG/OCIF equally and one specific for the homodimer. Characterization of circulating OPG/OCIF with these ELISAs revealed that the protein exists in human serum mainly in the monomeric form. The serum concentration of OPG/OCIF increased with age in both healthy Japanese men and women, and was significantly higher in postmenopausal women with osteoporosis than in age-matched controls. Within the osteoporotic group, serum OPG/OCIF concentrations were higher in patients with low bone mass. Serum OPG/OCIF concentrations were also significantly increased in those postmenopausal women with a high rate of bone turnover, as determined by increased serum bone-specific alkaline phosphatase and urinary excretion of pyridinoline and deoxypyridinoline. The results suggested that circulating OPG/OCIF levels are regulated by an age-related factor(s) and that the increased serum concentration may reflect a compensative response to enhanced osteoclastic bone resorption and the resultant bone loss rather than a cause of osteoporosis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0884-0431
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
518-27
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10234572-Adult, pubmed-meshheading:10234572-Aged, pubmed-meshheading:10234572-Aged, 80 and over, pubmed-meshheading:10234572-Animals, pubmed-meshheading:10234572-Antibodies, Monoclonal, pubmed-meshheading:10234572-Antibody Specificity, pubmed-meshheading:10234572-Bone Density, pubmed-meshheading:10234572-Bone Diseases, Metabolic, pubmed-meshheading:10234572-Case-Control Studies, pubmed-meshheading:10234572-Dimerization, pubmed-meshheading:10234572-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:10234572-Female, pubmed-meshheading:10234572-Glycoproteins, pubmed-meshheading:10234572-Humans, pubmed-meshheading:10234572-Male, pubmed-meshheading:10234572-Mice, pubmed-meshheading:10234572-Middle Aged, pubmed-meshheading:10234572-Osteoporosis, Postmenopausal, pubmed-meshheading:10234572-Osteoprotegerin, pubmed-meshheading:10234572-Protein Conformation, pubmed-meshheading:10234572-Receptors, Cytoplasmic and Nuclear, pubmed-meshheading:10234572-Receptors, Tumor Necrosis Factor, pubmed-meshheading:10234572-Recombinant Proteins
pubmed:year
1999
pubmed:articleTitle
Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
pubmed:affiliation
Research Institute of Life Science, Snow Brand Milk Products Co., Ltd, Tochigi, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't